Parasol Medtech

Parasol is developing a personalized solution to left atrial appendage closure to prevent stroke in patients with atrial fibrillation (AFib). AFib disrupts the heart’s normal rhythm, causing the upper chambers of the heart to beat irregularly. This abnormal rhythm allows blood to pool in a small pouch of the heart called the left atrial appendage, where clots can form and potentially travel to the brain, resulting in stroke.

Our mission is to reduce stroke risk and improve patient outcomes by delivering safer, more precise, and more effective heart-based solutions.

Parasol was founded on the belief that stroke prevention should not rely on one-size-fits-all technology. Every patient’s heart anatomy is different, and medical devices should reflect that reality.

Meet Dr. Atman Shah

Parasol Medtech Founder and Chief Medical Officer

A world renowned interventional cardiologist and Professor of Medicine at the University of Chicago, Dr. Shah is focused on scalable innovation to address structural heart disease. His expertise is in transcatheter interventions, particularly left atrial appendage closure and minimally invasive stroke prevention. He has closed over 1,000 left atrial appendages and travels the world teaching other physicians on this technique and technology.

Dr. Shah invented Parasol to enable a patient-focused, evidence-first, and regulatory-clear pathway. His work sits at the intersection of patient care, clinical execution, trial driven de-risking, and scalable device commercialization.

Our Team & Advisors

Parasol Medtech is led by Evan Singer, President and Chief Executive Officer, Dr. Atman Shah, Chief Medical Officer as well as advisors with experience commercializing technology from the University of Chicago. United by a shared focus - improving stroke prevention for patients with atrial fibrillation - Parasol’s leadership combines firsthand clinical insight with deep experience in medical device development. The company was founded to address real-world limitations seen in current stroke-prevention therapies, with an emphasis on safety, personalization, and long-term outcomes.

  • Evan Singer, CEO

    President and Chief Executive Officer

  • Alyssa Master, PhD

    Advisor & Director, Venture Development Polsky Center

  • Benjamin Cox, PhD

    Advisor & Senior Manager, Intellectual Property Polsky Center

  • Steve Gould MD

    Advisor & Polsky Tech Ventures Founder, Gould Consulting.

  • Jennifer Fried

    Advisor & CEO Flow Medical

What We’re Building

We are developing a novel, patient-specific left atrial appendage closure device designed to improve fit, sealing, and long-term safety. By prioritizing personalization and precision, our approach aims to:

  • Reduce procedural and post-implant complications.

  • Minimize residual leaks and clot formation.

  • Decrease reliance on lifelong anticoagulation for eligible patients.

Our device is being designed with clinical adoption, scalability, and regulatory pathways in mind.

Contact us

We welcome inquiries from investors, strategic partners, clinicians, and collaborators who share our mission to improve stroke prevention in atrial fibrillation.

If you’re interested in learning more about Parasol Medtech, our technology, clinical roadmap, or investment opportunity, we’d be glad to connect. Please email us at: info@parasolmedtech.com or fill out and submit the form on this page.